CD70 is a potential target biomarker in peripheral T‐cell lymphomas

F.V. receives research funding from CRISPR Therapeutics and Geron Corporation and received in the last 3 years honoraria from i3Health, Elsevier, America Registry of Pathology, Congressionally Directed Medical Research Program, and the Society of Haematology Oncology. S.P.I receives research funding from CRISPR, Seagen, Merck, Acrotech, Ono, Affimed, Rhizen, and Astra Zeneca. J.S., M.T.P, M.W., and K.T. are employees with equity interest in CRISPR Therapeutics. The remaining authors have no disclosures. This study was supported by the Translational Molecular Pathology-Immunoprofiling Laboratory (TMP-IL) at the Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center. The data that supports the findings of this study are available in the supplementary material of this article. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.